In June 2022, Enanta filed a lawsuit against Pfizer in a US district court in Massachusetts, claiming that the big pharma ...

HEALTH COVID drug Paxlovid, which helps prevent severe symptoms, will double in price as pandemic ebbs As Paxlovid goes commercial at a steep price, Pfizer vows to ensure ‘broad and equitable ...

About that $1,390 list price Pfizer sold the U.S. government 23.7 million five-day courses of Paxlovid, produced under an FDA emergency authorization, in 2021 and 2022, at a price of around $530 each.

Enanta Pharmaceuticals has initiated legal action against Pfizer (PFE) over a patent infringement related to Paxlovid, ...

Use of Pfizer Inc's COVID-19 antiviral Paxlovid spiked this week, but some doctors are reconsidering the pills for lower-risk patients after a U.S. public health agency warned that symptoms can ...

Pfizer studied the medication only for the full five days, so people should take them as prescribed, said Dr. Aida Habtezion, Pfizer's chief medical officer. How to get a Paxlovid prescription ...

Pfizer Inc's antiviral treatment Paxlovid reduces COVID-19 hospitalization and death rates in vaccinated and unvaccinated patients 65 years and older, according to a new study in Israel conducted ...

Pfizer plans to charge COVID patients around $1,400 for a five-day course of the antiviral drug Paxlovid — nearly triple the amount the US government paid during the coronavirus pandemic ...

Pfizer — the American pharmaceutical company that helped manufacture the COVID-19 vaccine — announced on Wednesday that it is hiking the price of its antiviral drug Paxlovid to $1,390 per ...

In a news release Tuesday, Pfizer said Paxlovid was not proven to reduce all Covid-19 symptoms for at least four consecutive days in these average-risk participants.

Pfizer stands to make a huge amount of money from Paxlovid. The investment bank SVB Leerink estimated that the drug would bring in $24 billion in global revenue in 2022 and $33 billion in 2023.

In the newly published trial result for Paxlovid, Pfizer showed an 89% reduction in risk of COVID-19-related hospitalization or death among more than 1,200 volunteers, half of whom received a placebo.